Applied DNA Sciences Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Applied DNA Sciences şirketinin kazançlarının yıllık 51.9% oranında düşmesi, yıllık gelirinin ise yıllık 37.5% oranında artması bekleniyor. EPS'nin yıllık 91.5% oranında büyümesi bekleniyor.

Anahtar bilgiler

-51.9%

Kazanç büyüme oranı

91.5%

EPS büyüme oranı

Life Sciences kazanç büyümesi	18.3%
Gelir büyüme oranı	37.5%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	22 Aug 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

The Market Doesn't Like What It Sees From Applied DNA Sciences, Inc.'s (NASDAQ:APDN) Revenues Yet As Shares Tumble 26%

Dec 20

Upgrade: Analysts Just Made A Notable Increase To Their Applied DNA Sciences, Inc. (NASDAQ:APDN) Forecasts

Aug 17

Applied DNA Sciences gains as it secures ~$3.6M proceeds from warrant exercise

Aug 09

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:APDN - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
9/30/2025	5	-13	N/A	N/A	2
9/30/2024	4	-7	N/A	N/A	2
6/30/2024	3	-8	-14	-13	N/A
3/31/2024	6	-13	-12	-11	N/A
12/31/2023	9	-7	-9	-8	N/A
9/30/2023	13	-10	-7	-6	N/A
6/30/2023	16	-7	-7	-7	N/A
3/31/2023	18	-5	-8	-7	N/A
12/31/2022	19	-7	-8	-8	N/A
9/30/2022	18	-8	-9	-9	N/A
6/30/2022	18	-12	-12	-10	N/A
3/31/2022	15	-15	-12	-10	N/A
12/31/2021	12	-14	-15	-13	N/A
9/30/2021	9	-14	-16	-13	N/A
6/30/2021	6	-14	-14	-12	N/A
3/31/2021	5	-14	-16	-13	N/A
12/31/2020	3	-15	-14	-13	N/A
9/30/2020	2	-13	-12	-11	N/A
6/30/2020	3	-10	-10	-10	N/A
3/31/2020	5	-9	-8	-8	N/A
12/31/2019	5	-8	-8	-8	N/A
9/30/2019	5	-9	-7	-7	N/A
6/30/2019	5	-11	-8	-8	N/A
3/31/2019	4	-12	-8	-7	N/A
12/31/2018	4	-12	-6	-6	N/A
9/30/2018	4	-12	-7	-7	N/A
6/30/2018	4	-11	-6	-5	N/A
3/31/2018	5	-11	N/A	-6	N/A
12/31/2017	4	-12	N/A	-8	N/A
9/30/2017	5	-13	N/A	-7	N/A
6/30/2017	5	-12	N/A	-9	N/A
3/31/2017	4	-13	N/A	-9	N/A
12/31/2016	4	-13	N/A	-9	N/A
9/30/2016	4	-12	N/A	-10	N/A
6/30/2016	7	-10	N/A	-9	N/A
3/31/2016	8	-9	N/A	-8	N/A
12/31/2015	9	-7	N/A	-7	N/A
9/30/2015	9	-12	N/A	-7	N/A
6/30/2015	6	-13	N/A	-7	N/A
3/31/2015	4	-14	N/A	-8	N/A
12/31/2014	3	-15	N/A	-9	N/A
9/30/2014	3	-13	N/A	-9	N/A
6/30/2014	3	-15	N/A	-8	N/A
3/31/2014	3	-15	N/A	-8	N/A
12/31/2013	2	-15	N/A	-8	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: APDN önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: APDN önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: APDN önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: APDN şirketinin gelirinin (yıllık 37.5% ) US pazarından (yıllık 9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: APDN şirketinin gelirinin (yıllık 37.5% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: APDN 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Applied DNA Sciences Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus revenue estimates fall by 20%

Consensus EPS estimates upgraded to US$5.32 loss

Consensus estimates of losses per share improve by 24%

Consensus EPS estimates upgraded to US$0.65 loss, revenue downgraded

Consensus revenue estimates fall by 49%

Consensus revenue estimates decrease by 13%, EPS upgraded

Recent updates

Applied DNA Sciences, Inc. Receives Written Notice from Nasdaq Regarding Minimum Bid Price Requirement

Applied DNA Sciences, Inc. announced that it has received funding

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $6.499893 million.

New major risk - Market cap size

Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement

Applied DNA Sciences, Inc.'s Applied DNA Clinical Labs, LLC Launches Mpox Clade I and Clade II Testing Service

Applied DNA Sciences, Inc. to Submit Application to New York State Department of Health to Expand Intended Use of Linea Mpox Virus 1.0 Assay to Mpox Clade I

Consensus revenue estimates fall by 20%

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Applied DNA Sciences, Inc. to Report Q3, 2024 Results on Aug 08, 2024

Applied DNA Sciences, Inc., Annual General Meeting, Sep 30, 2024

Applied DNA Sciences Receives Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price Requirement

Consensus EPS estimates upgraded to US$5.32 loss

Applied DNA Sciences, Inc. Receives Approval for TR8(TM) Pharmacogenomic (PGx) Testing Service from New York State Department of Health

Applied DNA Sciences, Inc. has completed a Composite Units Offering in the amount of $12 million.

New major risk - Share price stability

New major risk - Financial position

New major risk - Shareholder dilution

Consensus estimates of losses per share improve by 24%

Applied DNA Sciences, Inc. Receives A Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering.

Applied DNA Sciences, Inc. to Showcase Linea DNA and Linea IVT Platforms At 24Th Annual World Vaccine Congress

Consensus EPS estimates upgraded to US$0.65 loss, revenue downgraded

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

New major risk - Shareholder dilution

Applied DNA Sciences, Inc. to Report Q1, 2024 Results on Feb 08, 2024

Applied DNA Sciences, Inc., Annual General Meeting, Apr 15, 2024

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $3.436992 million.

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $3.437233 million.

The Market Doesn't Like What It Sees From Applied DNA Sciences, Inc.'s (NASDAQ:APDN) Revenues Yet As Shares Tumble 26%

Consensus revenue estimates fall by 49%

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Applied DNA Sciences Receives Non-Compliance Notice From Nasdaq

Applied DNA Sciences, Inc. to Report Q4, 2023 Results on Dec 07, 2023

Applied DNA Sciences, Inc. Extends Application of Linea(Tm) Ivt Platform to Sna (Self-Amplifying Mrna)

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $6.397939 million.

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $6.397939 million.

Applied DNA Sciences, Inc. Announces Appointment of Beverly Wolgast as Executive Director of Quality and cGMP Programs

Applied DNA Sciences, Inc. Announces Availability and First Customer Shipment of New Linea(TM) IVT Evaluation Kit

Applied DNA Sciences, Inc. Files Provisional Patent Applications for Methods of Double-Stranded RNA Mitigation in Next-Generation mRNA Production

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Applied DNA Sciences, Inc. to Report Q3, 2023 Results on Aug 10, 2023

Applied DNA Sciences, Inc., Annual General Meeting, Sep 19, 2023

New minor risk - Share price stability

Applied DNA Sciences, Inc. (NasdaqCM:APDN) acquired Spindle Biotech Inc. for $2.8 million.

Consensus revenue estimates decrease by 13%, EPS upgraded

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Applied DNA Sciences, Inc. to Report Q2, 2023 Results on May 11, 2023

Consensus revenue estimates increase by 12%

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Applied DNA Sciences, Inc. to Report Q1, 2023 Results on Feb 09, 2023

Applied DNA Sciences, Inc. Announces Publication of Peer-Reviewed Journal Article Validating Potential Use of linearDNA as New Class of DNA-Based Vaccines

Is Applied DNA Sciences (NASDAQ:APDN) In A Good Position To Invest In Growth?

Consensus revenue estimates fall by 20%

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

Price target decreased to US$7.00

Applied DNA Sciences, Inc. to Report Q4, 2022 Results on Dec 05, 2022

Applied DNA climbs 51% after winning large purchase order

Applied DNA Sciences, Inc.'s Subsidiary, Applied DNA Clinical Labs, LLC, Launches Monkeypox Testing Service

Applied DNA stock rises 12% on launching monkeypox testing service in New York

Applied DNA Submits PCR-Based Monkeypox Virus Diagnostic Test for Approval to New York State Department of Health

Applied DNA adds 17% as company seeks approval for monkeypox test in New York

Consensus estimates of losses per share improve by 19%

Upgrade: Analysts Just Made A Notable Increase To Their Applied DNA Sciences, Inc. (NASDAQ:APDN) Forecasts

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations